Skip to content

Nephrocalcinosis in Very Low Birth Weight Infants

Nephrocalcinosis in Very Low Birth Weight Infants: an Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04860583
Enrollment
265
Registered
2021-04-27
Start date
2012-01-01
Completion date
2020-12-31
Last updated
2021-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infant; Premature, Light-For-Dates

Brief summary

Extremely premature children benefit from specific follow-up that requires high nutritional intake and the use of specific therapies that expose them to the risk of nephrocalcinosis. Other identified risk factors are extreme prematurity and intrauterine growth restriction. The incidence of nephrocalcinosis in very premature infants is unclear, ranging from 7 to 64%. Most studies are observational and only few case-control studies can properly analyse the risk factors for nephrocalcinosis in significant populations that include only preterm infants. This nephrocalcinosis of prematurity regresses spontaneously in more than half of the cases, but has been associated with a risk of long-term complications: impaired renal function, high blood pressure, etc. This is an aggravating factor in the context of prematurity, which has been associated with an increased risk of renal impairment and hypertension in childhood and adulthood. For all these reasons, nutritional intakes and therapeutics are monitored very closely and a renal ultrasound is routinely performed at discharge at 35 weeks of corrected gestational age in all children who are born at a gestational age ≤ 32 weeks and/or birth weight ≤ 1500 g.

Interventions

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Newborns with a gestational age \<= 32 weeks and/or birthweight \<=1500g

Exclusion criteria

* Newborns with kidney malformation

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of nephrocalcinosisAt week 35 of corrected gestational agePresence/absence of nephrocalcinosis will be checked by ultrasound

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026